Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprachoroidal CLS-TA + Anti-VEGF for RVO (TOPAZ)
NCT03203447Phase 3Terminated
- Sponsor
- Clearside Biomedical
- Start
- Mar 2018
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of triamcinolone in macular edema and retinal vein occlusion (RVO) (2 arms), sponsored by Clearside Biomedical. Primary endpoint: Proportion of Subjects Demonstrating >= 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) at 2 months. Started Mar 2018; status: terminated.
02
Drugs
triamcinolone
03
Conditions
macular edemaretinal vein occlusion (RVO)
Beyond the preview
Go deeper on NCT03203447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203447.